Retirement Systems of Alabama Boosts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Retirement Systems of Alabama raised its position in Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) by 0.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 165,445 shares of the biopharmaceutical company’s stock after purchasing an additional 728 shares during the quarter. Retirement Systems of Alabama owned 0.13% of Halozyme Therapeutics worth $6,115,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Convergence Investment Partners LLC purchased a new position in shares of Halozyme Therapeutics during the fourth quarter worth approximately $259,000. Alliance Wealth Advisors LLC UT increased its position in shares of Halozyme Therapeutics by 14.6% during the fourth quarter. Alliance Wealth Advisors LLC UT now owns 9,610 shares of the biopharmaceutical company’s stock worth $355,000 after acquiring an additional 1,221 shares during the period. Headlands Technologies LLC increased its position in shares of Halozyme Therapeutics by 1,068.2% during the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 1,613 shares during the period. Truist Financial Corp increased its position in shares of Halozyme Therapeutics by 0.6% during the fourth quarter. Truist Financial Corp now owns 102,622 shares of the biopharmaceutical company’s stock worth $3,793,000 after acquiring an additional 563 shares during the period. Finally, Parkside Financial Bank & Trust purchased a new position in shares of Halozyme Therapeutics during the fourth quarter worth approximately $64,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total transaction of $416,400.00. Following the completion of the sale, the senior vice president now directly owns 156,558 shares in the company, valued at $6,519,075.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders sold 30,000 shares of company stock worth $1,196,800. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $39.91 on Friday. The company has a market cap of $5.07 billion, a price-to-earnings ratio of 18.91, a price-to-earnings-growth ratio of 0.47 and a beta of 1.26. Halozyme Therapeutics, Inc. has a twelve month low of $29.85 and a twelve month high of $45.00. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. The company has a 50 day moving average of $39.99 and a two-hundred day moving average of $37.89.

Halozyme Therapeutics (NASDAQ:HALOGet Free Report) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The firm had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. As a group, analysts predict that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. TheStreet lowered shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. Benchmark reissued a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. TD Cowen assumed coverage on shares of Halozyme Therapeutics in a report on Thursday, February 29th. They set an “outperform” rating and a $54.00 price objective on the stock. Finally, The Goldman Sachs Group cut their price objective on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a report on Thursday, January 18th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $53.29.

View Our Latest Stock Report on Halozyme Therapeutics

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Further Reading

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.